Company welcomes three expert scientific advisors to highly experienced team of biotech professionals
DENVER (October 4, 2017) – Colorado-based biotech company Next Frontier Biosciences today announced its Scientific Advisory Board, rounding out the company’s expert lineup of biotech and cannabis professionals. With plans to launch its Verra Wellness line of purified cannabinoid products for the medical and adult-use marijuana markets in Colorado this month, Next Frontier Biosciences, a trailblazer in the cannabis space, continuously strives to use high quality and purified ingredients that provide safe and natural alternatives for cannabis patients and adult-use consumers alike.
“Research and scientific formulation are at the heart of everything we do,” said Paul Johnson, Ph.D., Co-Founder & Chief Scientific Officer of Next Frontier Biosciences. “Backed by a team of educated and highly experienced thought leaders, Next Frontier Biosciences is emerging at the forefront of innovation in the cannabis industry. Ahead of our upcoming product launch, we are proud to have engaged an accomplished group of professionals that will uphold and advocate for our company values, demonstrating strong commitment to cutting-edge research, scientific excellence and integrity.”
Dr. Rav Ivker, D.O., joins the Scientific Advisory Board as a holistic family physician, cannabis clinician, health educator, spiritual counselor, author and healthcare visionary. In his current practice, Fully Alive Medicine in Boulder, Colorado, Dr. Ivker’s primary focus is the treatment and prevention of chronic pain using a holistic approach that includes medical marijuana.
Dr. Ivker has been practicing medicine for more than 45 years. His original practice, Columbine Medical Center, became the first combined family practice/minor emergency center in Colorado, a forerunner of today’s Urgent Care Centers. He is the Co-Founder and Past-President of the American Board of Integrative Holistic Medicine, a Past-President of the American Holistic Medical Association and the author of the best-selling book, Sinus Survival.
His latest book, Cannabis for Chronic Pain: A Proven Prescription for Using Marijuana to Relieve Your Pain & Heal Your Life, provides the first authoritative and comprehensive guide for treating chronic pain with medical marijuana. Published by Simon & Schuster in September, this excellent resource can be found in bookstores and online.
“On the market today, there is currently an unmet medical need for well-characterized, purified cannabinoid products that are scientifically formulated to provide accurate dosing, improved bioavailability and reduced psychogenic effects,” Dr. Ivker said. “However, Next Frontier Biosciences is developing those very products, ultimately closing the gap and revolutionizing the industry by providing the public with a safe, non-inhalable and highly effective option that allows them to function well while relieving a myriad of uncomfortable symptoms.”
Shawn Zinnen, Ph.D., is Chief Executive Officer of MBC Pharma Inc., a pharmaceutical company focused on discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. Dr. Zinnen joins the Scientific Advisory Board as an experienced pharmaceutical executive and discovery scientist with a demonstrated track record of success in preclinical and early-stage clinical drug development. Dr. Zinnen has managed interdisciplinary teams of both industry and academic scientists solving pharmacology-related problems for diseases ranging from cancer to asthma to macular degeneration.
Prior to joining MBC Pharma, Dr. Zinnen served in various roles of increasing responsibility at Sirna Therapeutics, Inc. (previously Ribozyme Pharmaceuticals Inc.), where he helped advance drug compounds from discovery stage and into human clinical trials. Dr. Zinnen graduated with a Ph.D. in Biochemistry and Genetics from Duke University and conducted post-doctoral research at the University of Colorado at Boulder as an NIH Fellow. He has authored or coauthored 17 papers and 54 patents.
“I am impressed with Next Frontier Biosciences’ experienced team and their use of solid analytical science to advance the industry,” Dr. Zinnen said. “I look forward to bringing my own background in pharmaceutical development to help further investigate the healing potential of cannabis on a broader scale.”
Completing the board is Laurie K. Mischley, ND Ph.D. MPH. Dr. Mischley joins the team with a degree in naturopathic medicine (ND) from Bastyr University, as well as degrees in epidemiology (MPH) and nutritional sciences (Ph.D.) from the University of Washington.
Dr. Mischley is Principle Investigator of the Survey of Cannabis Use (www.CannabisSurvey.org), an international study that gives cannabis users a forum to tell physicians, researchers, policy-makers and the public why and how they use cannabis. She has published on the medical use of cannabis, including the recent Journal of Pain Research article “Cannabis as a Substitute for Prescription Drugs – a Cross-Sectional Study,” and differing experiences between men and women who use cannabis. In addition, she has recently completed a study on cannabis use for Parkinson’s disease tremor.
Most of Dr. Mischley’s work is focused on identifying the nutritional requirements unique to individuals with neurodegenerative diseases. She founded the Social Purpose Corporation, NeurRx, developed an outcome measure to assess PD severity, www.PROPD.org, and is author of the books Natural Therapies for Parkinson’s Disease and Survey of Cannabis Use: Confessions, Insights, and Opinions.
“Patients and consumers need to know that they have options,” Dr. Mischley said. “Furthermore, they need to be educated on what those options are so that they can feel empowered to make the right decision when it comes to finding a well-suited cannabis product. I am passionate about helping to inform the public about Next Frontier Biosciences’ line of products as a research-based, science-backed option with the capability of changing their lives for the better.”
Founded in 2014, Next Frontier Biosciences has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. Next Frontier Biosciences’ proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.
For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or [email protected].
About Next Frontier Biosciences:
Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.
The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.
Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.
Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.